Pulmonary Fibrosis Clinical Trials in Beijing, Beijing Municipality
7 recruitingBeijing, Beijing Municipality, China
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd.110 enrolled1 locationNCT05139719
Recruiting
Phase 3
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Phase 1Phase 2
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
TumorCardiovascular DiseasesPulmonary Fibrosis+3 more
Peking Union Medical College Hospital30 enrolled1 locationNCT07464132
Recruiting
Phase 3
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Beijing Tide Pharmaceutical Co., Ltd508 enrolled1 locationNCT07464912
Recruiting
Not Applicable
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
Pulmonary FibrosisTransbronchial Cryobiopsy
China-Japan Friendship Hospital100 enrolled1 locationNCT06251687
Recruiting
Phase 1
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Pulmonary Fibrosis
Peking Union Medical College Hospital80 enrolled1 locationNCT05121779
Recruiting
Phase 2Phase 3
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06125327